CORT Latest Press Releases

-- October 20, 2026 --

2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes Business Wire 4:00 PM

-- October 9, 2026 --

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Erasca, Inc. (ERAS), DICK'S Sporting Goods, Inc. (DKS), Corcept Therapeutics Incorporated (CORT), and Charter Communications, Inc. (CHTR) Globe Newswire 11:55 AM

-- September 23, 2026 --

Corcept Announces Planned Leadership Transition Business Wire 8:00 AM

-- September 18, 2026 --

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli (Relacorilant) Business Wire 8:00 AM

-- September 4, 2026 --

Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600 PRNewswire 7:16 PM

-- July 29, 2026 --

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update Business Wire 4:05 PM

-- July 22, 2026 --

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call Business Wire 4:05 PM

-- June 25, 2026 --

Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm PRNewswire 6:41 PM

-- June 17, 2026 --

Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm Globe Newswire 10:10 PM

Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing's Syndrome Business Wire 4:28 PM

-- June 6, 2026 --

Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym Business Wire 4:45 PM

-- May 29, 2026 --

Corcept Presents New Data at ASCO 2026: Lifyorli Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure Business Wire 4:33 PM

-- May 27, 2026 --

Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing's Syndrome Business Wire 8:00 AM

Market Data Delayed 15 Minutes